Cardinal Health, Inc. (NYSE:CAH) is included among the 20 Best Performing Dividend Stocks in 2025. Cardinal Health (CAH) Repositions for Growth with Specialty and Services Cardinal Health, Inc. (NYSE:CAH)’s market-beating performance reflects a business that has changed direction and executed well. By shifting more of its focus toward higher-margin areas such as specialty pharmaceuticals and managed services, earnings growth has picked up in a meaningful way. Sell-side forecasts suggest that momentum sho ...

Group 1: Cardinal Health - Cardinal Health's share prices have surged nearly 74% year to date, with significant gains following a strong quarterly earnings report [3][4] - Fiscal first-quarter 2026 revenue reached $64 billion, a 22% increase from the previous year, exceeding analyst expectations [3][5] - Adjusted earnings per share (EPS) of $2.55 surpassed Wall Street's forecasts, with estimates predicting EPS growth of 19% and 12.6% for the current and next fiscal years, respectively [5] Group 2: Loews - Loews shares have increased by 24% year to date, reflecting a turnaround from weak returns in the 2010s [6][8] - The company, controlled by the Tisch family, focuses on increasing intrinsic value per share and is actively repurchasing shares [9] - Loews owns significant stakes in CNA Financial and has interests in energy pipelines, hotels, and packaging, making it an attractive option for conservative investors seeking steady returns [8][9] Group 3: SanDisk - SanDisk's shares have surged over sixfold since splitting from Western Digital in February, with a 70% increase in the past month [10][11] - The company benefits from a NAND shortage, with robust demand for memory chips driven by artificial intelligence infrastructure [10] - SanDisk has raised NAND flash contract prices by 50%, and the market currently values its shares at a forward price-to-earnings (P/E) ratio of around 19, indicating potential for continued growth [10][12]

Financial Data and Key Metrics Changes - The company has increased its EPS guidance to a range of $15.85 to $16, reflecting strong performance throughout fiscal year 2025 [8] - The U.S. Healthcare Solutions segment has been a significant driver of growth, contributing to broad-based strong growth across the U.S. business [7][10] Business Line Data and Key Metrics Changes - Specialty pharmaceuticals have been identified as a key growth driver, with a focus on strengthening the company's position in this market [3][7] - The company has seen strong utilization trends and growth in sales of specialty products to physician practices and health systems [10] Market Data and Key Metrics Changes - The international segment, which accounts for 15% of operating income, has faced challenges, particularly in the global specialty logistics and consulting businesses [61][63] - There is an expectation of improved performance in the international business for fiscal year 2026 due to a rebound in clinical trial activity [66] Company Strategy and Development Direction - The company has outlined three growth priorities: leading with market leaders, strengthening its position in specialty markets, and enhancing patient access to pharmaceuticals [2][4] - Four strategic drivers have been identified: digital transformation, growth-oriented investments, productivity improvements, and talent and culture [5][6] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the market, citing strong fundamentals and a favorable environment for growth [13] - The company is taking a prudent approach to long-term guidance, evaluating market conditions and performance regularly [13] Other Important Information - The integration process for Retina Consultants of America is progressing well, with a focus on capital investment and synergy realization [46] - The company is committed to investing approximately $600 million in CapEx, primarily in technology and infrastructure [73] Q&A Session Summary Question: What are the key drivers of the company's strong growth this year? - Management highlighted strong utilization trends, growth in specialty product sales, and broad-based results across U.S. businesses as key drivers [10] Question: How does the company view the sustainability of its growth? - Management indicated that while recent performance has outperformed long-term guidance, they remain cautious and will evaluate all moving pieces before making adjustments [13] Question: What is the company's approach to vaccine demand planning? - The company accumulates initial booking expectations from customers to prepare for vaccine shipments, noting that COVID vaccine demand has become more significant due to retail channel distribution [25] Question: How is the company addressing the challenges in the international market? - Management acknowledged the challenges faced in the international segment but expressed optimism for recovery in fiscal year 2026 due to rebounding clinical trial activity [66] Question: What are the company's capital deployment priorities? - The company plans to invest in business growth, strategic M&A, opportunistic share repurchases, and maintain a growing dividend [73]